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DrugAbstract Nanotherapy is an actual newest mode of treatment that can be applied for cancer ther-
apy. To imagine and test the hypothesis and idea regarding the new hypothesised nanotherapeutic
system, there are many issues to be addressed including the change of properties of substances at the
nano-level, the use of in vitro studies for testing the new drug and the safety of the new nano-
substance.
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pid growth and development. The applications of nanomedi-
cine can be either diagnosis or therapy [1]. For the speciﬁc
issue of using nanomedicine for therapeutic purposes, it is
called ‘nanotherapy’ [1]. Nanotherapy is an actual newest
mode of treatment in medicine. Focussing on the principles
of nanotherapy, the use of novel nanotherapeutic agents aim-
ing at a therapeutic effect at the nano-level is expected. Of sev-
eral medical disorders, nanotherapy is presently widely studied
with respect to the treatment for cancer, a disease with no hope
of cure in the past [2]. There are many ongoing researches and
studies on this speciﬁc topic. The new hypotheses and ideas on
this issue are quite useful. A recent publication in the journal
on the possibility to use a new nano-drug delivery system to
eradicate cancer stem cells is a good paper on cancer nanother-
apy [3]. Indeed, to construct a new nano-drug delivery systemniversity of Medical Sciences. Pub
h/
/j.jmhi.2012.10.002is an important step in ﬁnding a new, effective nanotherapeutic
method. However, as noted in another previous article in the
journal [4], the process is complex and might be difﬁcult. To
imagine and test the hypothesis and idea on the new hypothe-
sised nanotherapeutic system, there are many issues to be
addressed.
First, the concept of the change of physical and chemical
properties of a substance when it is scaled down to the nano-
level must be kept in mind. Many known properties of a sub-
stance when it is in its large form might not last when it reaches
the nano-form [4]. (Further, the stability of the newly devel-
oped nano-drug to remain its nano-form is very important).
This is an important issue to consider in a nano-pharmaceuti-
cal process [4]. Second, size is an important determinant for the
success of a therapeutic attack. Simply, the transportation of a
nano-drug into the targeted site at the target cell must be basedlished by Elsevier Ltd. Open access under CC BY-NC-ND license.
4 V. Wiwanitkiton appropriate size [1]. Many molecules have to pass thorough
the cell pore to enter into the cells and further present action.
This is very important since larger molecules might not suc-
cessfully pass thorough the smaller pores of cells. Although
the molecule is at a nano-level, it is still difﬁcult for it to pass
the cellular pore if its size is still larger than the pore diameter.
It is important to take note that many new studies are usually
based on in vitro ﬁndings and the observed actions might not
be the same as the in vivo situation. In an in vivo case, there
can be many confounding factors that might alter the desired
activities that can be observed in a pure in vitro study [4]. Fur-
thermore, most of the present evidence from in vitro studies is
from tests on cancer cell cultures [5]. Certainly, the cancer cell
is not a normal physiological cell. Differences in cell biological
processes can be expected. The observed response and reaction
between cancer cells and a new studied nano-agent cannot be
used as a reference to the exact reaction in a normal cell [5].
Finally, the toxicity of the nano-substance must be mentioned
[6]. As a nano-drug, signiﬁcant reduction of required dosage
for therapeutic purpose can be expected [7]. Basically, a
nano-material is usually not a molecule with high selectivity
to a speciﬁc cell. Hence, when the new drug becomes very
small, it can simply enter into many cells and might cause un-
wanted toxicity. The nano-substance is a new thing and we stillhave little knowledge on it. The toxicity of the nanoparticle is a
real issue but little mentioned. These factors should be kept in
mind for any work on hypothesising for new nano-agents for
nanotherapy.
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